Patents by Inventor Hanne Gron
Hanne Gron has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9260530Abstract: The invention relates to immunotherapeutic compositions and methods for the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies and autoimmune diseases and disorders, using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies.Type: GrantFiled: August 1, 2013Date of Patent: February 16, 2016Assignee: Duke UniversityInventors: Thomas F. Tedder, Yasuhito Hamaguchi, Hanne Gron, Norihito Yazawa
-
Patent number: 8779089Abstract: Compositions and methods for tissue repair are provided including cell binding peptides and growth factor binding peptides. The cell binding peptides bind to one or more of stem cells, fibroblasts, or endothelial cells. The growth factor binding peptides include platelet derived growth factor (PDGF) binding peptides and growth differentiation factor (GDF) binding peptides. The tissue for repair includes tendon, muscle, connective tissue, ligament, cardiac tissue, vascular tissue, or dermis. Implantable devices for tissue repair are provided to which the cell and growth factor binding peptides are attached, such as acellular extracellular matrix having attached binding peptide.Type: GrantFiled: November 18, 2010Date of Patent: July 15, 2014Assignee: Affinergy, LLCInventors: Isaac Gilliam Sanford, Michelle Steffen Jansen, Paul Theodore Hamilton, Jonathan Allen Hodges, Shrikumar Ambujakshan Nair, Yuchen Chen, Martyn Kerry Darby, Hanne Gron, Ganesan Sathya
-
Patent number: 8691946Abstract: Compositions and methods for tissue repair are provided including cell binding peptides and growth factor binding peptides. The cell binding peptides bind to one or more of stem cells, fibroblasts, or endothelial cells. The growth factor binding peptides include platelet derived growth factor (PDGF) binding peptides and growth differentiation factor (GDF) binding peptides. The tissue for repair includes tendon, muscle, connective tissue, ligament, cardiac tissue, vascular tissue, or dermis. Implantable devices for tissue repair are provided to which the cell and growth factor binding peptides are attached, such as acellular extracellular matrix having attached binding peptide.Type: GrantFiled: May 17, 2011Date of Patent: April 8, 2014Assignee: Affinergy, LLCInventors: Isaac Gilliam Sanford, Martyn Kerry Darby, Jonathan Allen Hodges, Shrikumar Ambujakshan Nair, Yuchen Chen, Paul Theodore Hamilton, Ganesan Sathya, Hanne Gron, Michelle Steffen Jansen
-
Publication number: 20140056896Abstract: The invention relates to immunotherapeutic compositions and methods for the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies and autoimmune diseases and disorders, using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies.Type: ApplicationFiled: August 1, 2013Publication date: February 27, 2014Applicant: DUKE UNIVERSITYInventors: Thomas F. Tedder, Yasuhito Hamaguchi, Hanne Gron, Norihito Yazawa
-
Patent number: 8637455Abstract: The presently disclosed subject matter relates to peptides having binding affinity for glycopeptide antibiotics and methods and compositions for delivering glycopeptide antibiotic to the surface of medical devices. The peptide compositions can comprise a peptide having binding affinity for a surface material of a medical device that is coupled to the peptide having binding affinity for glycopeptide antibiotic. Also provided are methods of applying the peptide compositions to a medical device by contacting the peptide compositions with a surface of the medical device. In addition, kits are provided comprising the peptide compositions.Type: GrantFiled: October 17, 2008Date of Patent: January 28, 2014Assignees: Affinergy, LLC, DePuy Synthes Products, LLCInventors: Martyn K. Darby, Isaac G. Sanford, R. Edward Benson, Hanne Gron, Paul T. Hamilton, Shrikumar A. Nair, Doug Buechter, Elliott Gruskin
-
Patent number: 8444973Abstract: The invention relates to immunotherapeutic compositions and methods for the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies and autoimmune diseases and disorders, using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies.Type: GrantFiled: September 17, 2010Date of Patent: May 21, 2013Assignee: Duke UniversityInventors: Thomas F. Tedder, Yasuhito Hamaguchi, Hanne Gron, Norihito Yazawa
-
Publication number: 20130084294Abstract: The invention relates to immunotherapeutic compositions and methods for the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies and autoimmune diseases and disorders, using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies.Type: ApplicationFiled: September 4, 2012Publication date: April 4, 2013Applicant: DUKE UNIVERSITYInventors: Thomas F. Tedder, Yasuhito Hamaguchi, Hanne Gron, Norihito Yazawa
-
Publication number: 20110223142Abstract: Compositions and methods for tissue repair are provided including cell binding peptides and growth factor binding peptides. The cell binding peptides bind to one or more of stem cells, fibroblasts, or endothelial cells. The growth factor binding peptides include platelet derived growth factor (PDGF) binding peptides and growth differentiation factor (GDF) binding peptides. The tissue for repair includes tendon, muscle, connective tissue, ligament, cardiac tissue, vascular tissue, or dermis. Implantable devices for tissue repair are provided to which the cell and growth factor binding peptides are attached, such as acellular extracellular matrix having attached binding peptide.Type: ApplicationFiled: May 17, 2011Publication date: September 15, 2011Applicant: AFFINERGY, INC.Inventors: Isaac Gilliam Sanford, Martyn Kerry Darby, Shrikumar Ambujakshan Nair, Jonathan Allen Hodges, Yuchen Chen, Ganesan Sathya, Hanne Gron, Michelle Steffen Jansen, Paul Theodore Hamilton
-
Patent number: 7977313Abstract: Compositions are provided comprising a family of peptides having binding specificity for bone, and their use to produce coating compositions. The coating compositions are used to deliver a pharmaceutically active agent to bone, and are used in methods related to bone implants, bone repair, and bone-related diseases.Type: GrantFiled: April 22, 2008Date of Patent: July 12, 2011Assignees: Affinergy, Inc., Synthes USA, LLCInventors: Hanne Gron, David Duffin, Doug Buechter, Elliott Gruskin, Michael Lehmicke
-
Publication number: 20110117167Abstract: Compositions and methods for tissue repair are provided including cell binding peptides and growth factor binding peptides. The cell binding peptides bind to one or more of stem cells, fibroblasts, or endothelial cells. The growth factor binding peptides include platelet derived growth factor (PDGF) binding peptides and growth differentiation factor (GDF) binding peptides. The tissue for repair includes tendon, muscle, connective tissue, ligament, cardiac tissue, vascular tissue, or dermis. Implantable devices for tissue repair are provided to which the cell and growth factor binding peptides are attached, such as acellular extracellular matrix having attached binding peptide.Type: ApplicationFiled: November 18, 2010Publication date: May 19, 2011Applicant: AFFINERGY, INC.Inventors: Isaac Gilliam Sanford, Michelle Steffen Jansen, Paul Theodore Hamilton, Jonathan Allen Hodges, Shrikumar Ambujakshan Nair, Yuchen Chen, Martyn Kerry Darby, Hanne Gron, Ganesan Sathya
-
Publication number: 20110117168Abstract: Compositions and methods for tissue repair are provided including cell binding peptides and growth factor binding peptides. The cell binding peptides bind to one or more of stem cells, fibroblasts, or endothelial cells. The growth factor binding peptides include platelet derived growth factor (PDGF) binding peptides and growth differentiation factor (GDF) binding peptides. The tissue for repair includes tendon, muscle, connective tissue, ligament, cardiac tissue, vascular tissue, or dermis. Implantable devices for tissue repair are provided to which the cell and growth factor binding peptides are attached, such as acellular extracellular matrix having attached binding peptide.Type: ApplicationFiled: November 18, 2010Publication date: May 19, 2011Applicant: AFFINERGY, INC.Inventors: Ganesan Sathya, Michelle Steffen Jansen, Paul Theodore Hamilton, Jonathan Allen Hodges, Shrikumar Ambujakshan Nair, Hanne Gron
-
Publication number: 20110104150Abstract: The invention relates to immunotherapeutic compositions and methods for the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies and autoimmune diseases and disorders, using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies.Type: ApplicationFiled: September 17, 2010Publication date: May 5, 2011Applicant: DUKE UNIVERSITYInventors: Thomas F. Tedder, Yasuhito Hamaguchi, Hanne Gron, Norihito Yazawa
-
Publication number: 20110038912Abstract: The presently disclosed subject matter relates to peptides having binding affinity for glycopeptide antibiotics and methods and compositions for delivering glycopeptide antibiotic to the surface of medical devices. The peptide compositions can comprise a peptide having binding affinity for a surface material of a medical device that is coupled to the peptide having binding affinity for glycopeptide antibiotic. Also provided are methods of applying the peptide compositions to a medical device by contacting the peptide compositions with a surface of the medical device. In addition, kits are provided comprising the peptide compositions.Type: ApplicationFiled: October 17, 2008Publication date: February 17, 2011Applicants: Affinergy Inc., Synthes USA, LLCInventors: Martyn K. Darby, Isaac G. Sanford, R. Edward Benson, Hanne Gron, Paul T. Hamilton, Shrikumar A. Nair, Doug Buechter, Elliott Gruskin
-
Publication number: 20100158901Abstract: The invention relates to immunotherapeutic compositions and methods for the treatment of autoimmune diseases and disorders in human subjects using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies.Type: ApplicationFiled: December 1, 2008Publication date: June 24, 2010Applicant: Duke UniversityInventors: Thomas F. Tedder, Yasuhito Hamaguchi, Hanne Gron, Norihito Yazawa
-
Publication number: 20100098737Abstract: The presently disclosed subject matter relates to peptides having binding affinity for glycopeptide antibiotics and methods and compositions for delivering glycopeptide antibiotic to the surface of medical devices. The peptide compositions can comprise a peptide having binding affinity for a surface material of a medical device that is coupled to the peptide having binding affinity for glycopeptide antibiotic. Also provided are methods of applying the peptide compositions to a medical device by contacting the peptide compositions with a surface of the medical device. In addition, kits are provided comprising the peptide compositions.Type: ApplicationFiled: October 17, 2008Publication date: April 22, 2010Applicant: Affinergy, Inc.Inventors: Martyn Kerry Darby, Isaac Gilliam Sanford, Ray Edward Benson, III, Hanne Gron, Paul Theodore Hamilton, Shrikumar Ambujakshan Nair
-
Publication number: 20090285808Abstract: The invention relates to immunotherapeutic compositions and methods for the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies, using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies.Type: ApplicationFiled: March 10, 2009Publication date: November 19, 2009Applicant: Duke UniversityInventors: Thomas F. Tedder, Yasuhito Hamaguchi, Hanne Gron, Norihito Yazawa
-
Publication number: 20080268015Abstract: Compositions are provided comprising a family of peptides having binding specificity for bone, and their use to produce coating compositions. The coating compositions are used to deliver a pharmaceutically active agent to bone, and are used in methods related to bone implants, bone repair, and bone-related diseases.Type: ApplicationFiled: April 22, 2008Publication date: October 30, 2008Inventors: Hanne Gron, David Duffin
-
Publication number: 20060263357Abstract: The invention relates to immunotherapeutic compositions and methods for the treatment of autoimmune diseases and disorders in human subjects using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies.Type: ApplicationFiled: May 5, 2006Publication date: November 23, 2006Inventors: Thomas Tedder, Yasuhito Hamaguchi, Hanne Gron, Norihito Yazawa
-
Publication number: 20060233791Abstract: The invention relates to immunotherapeutic compositions and methods for the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies, using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies.Type: ApplicationFiled: February 15, 2006Publication date: October 19, 2006Inventors: Thomas Tedder, Yasuhito Hamaguchi, Hanne Gron, Norihito Yazawa
-
Publication number: 20020127232Abstract: Activation of &agr;2-macroglobulin (&agr;2M) with a nucleophilic compound followed by incubation of the activated &agr;2M at elevated temperature with a biomolecule results in covalent incorporation of the intact biomolecule into the &agr;2M molecule, without the use of proteinases. The thus-formed structurally defined and stable complex may be used as an antigen for stimulating the immune response, for example, in the form of a vaccine. Enhanced antigen presentation of a particular biomolecule is provided, especially for those that are poorly immunogenic; reduction of the immunodominance of particular epitopes is also provided.Type: ApplicationFiled: November 20, 2001Publication date: September 12, 2002Inventors: Salvatore Pizzo, Hanne Gron